Romidepsin for the treatment of non-Hodgkin’s lymphoma

Bibliography

• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476(7360):298-303
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37(4):391-400
   PubMed Web of Science ®Google Scholar
• Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 2014;143(3):323-36
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409(2):581-9
   PubMed Web of Science ®Google Scholar
• Heerboth S, Lapinska K, Snyder N, et al. Use of epigenetic drugs in disease: an overview. Genet Epigenet 2014;6:9-19
   PubMedGoogle Scholar
• Ren M, Leng Y, Jeong M, et al. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004;89(6):1358-67
   PubMed Web of Science ®Google Scholar
• Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(10):3697-702
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Fuino L, Stobaugh C, et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003;101(8):3236-9
   PubMed Web of Science ®Google Scholar
• Lee JH, Choy ML, Ngo L, et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 2010;107(33):14639-44
   PubMed Web of Science ®Google Scholar
• Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(3):673-8
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Maggio SC, et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 2008;7(10):3285-97
   PubMed Web of Science ®Google Scholar
• Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004;13(5):627-38
   PubMed Web of Science ®Google Scholar
• Robert T, Vanoli F, Chiolo I, et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 2011;471(7336):74-9
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102(24):8567-72
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Lembersky D, Kramer L, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010;115(22):4478-87
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Knutson SK, Jiang G, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 2010;18(5):436-47
   PubMed Web of Science ®Google Scholar
• Wang R, Brunner T, Zhang L, Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 1998;17(12):1503-8
   PubMed Web of Science ®Google Scholar
• Warrener R, Beamish H, Burgess A, et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 2003;17(11):1550-2
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Lembersky D, Kramer L, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010;115(22):4478-87
   PubMed Web of Science ®Google Scholar
• Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007;13(24):7237-42
   PubMed Web of Science ®Google Scholar
• Ropero S, Fraga MF, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006;38(5):566-9
   PubMed Web of Science ®Google Scholar
• Fiskus W, Rao R, Fernandez P, et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2008;112(7):2896-905
   PubMed Web of Science ®Google Scholar
• Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008;112(5):1886-93
   PubMed Web of Science ®Google Scholar
• Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008;68(10):3785-94
   PubMed Web of Science ®Google Scholar
• Chakraborty AR, Robey RW, Luchenko VL, et al. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood 2013;121(20):4115-25
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Daud AI, et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92(2):223-37
   PubMed Web of Science ®Google Scholar
• Yardley DA, Ismail-Khan R, Klein P. Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI). J Clin Oncol 2011;29(Suppl 27):abstract 268
   Google Scholar
• Panobinostat Approved for Multiple Myeloma. Cancer discovery. 2015
   Google Scholar
• Dai Y, Chen S, Wang L, et al. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-kappaB and Bim. Br J Haematol 2011;153(2):222-35
   PubMed Web of Science ®Google Scholar
• Dai Y, Guzman ML, Chen S, et al.et al. Nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 2010;151(1):70-83
   PubMed Web of Science ®Google Scholar
• Deng C, Lipstein M, Rodriguez R, et al. The Novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-kappaB. Clin Cancer Res 2015;21(1):134-45
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Kolla SS, et al. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther 2007;6(2):692-702
   PubMed Web of Science ®Google Scholar
• Holkova B, Kmieciak M, Perkins EB, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and “nonhybrid” (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 2014;20(22):5652-62
   PubMed Web of Science ®Google Scholar
• Holkova B, Supko JG, Ames MM, et al. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 2013;19(7):1873-83
   PubMed Web of Science ®Google Scholar
• Holkova B, Perkins EB, Ramakrishnan V, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 2011;17(10):3388-97
   PubMed Web of Science ®Google Scholar
• Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66(7):3773-81
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108(10):3441-9
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15(11):1195-206
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011;118(24):6274-83
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Kmieciak M, et al. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther 2013;12(6):878-89
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhang Y, Chen S, et al. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 2015;29(4):807-18
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Patel H, Nguyen T, et al. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 2013;19(2):404-14
   PubMed Web of Science ®Google Scholar
• Khan KH, Blanco-Codesido M, Molife LR. Cancer therapeutics: Targeting the apoptotic pathway. Crit Rev Oncol Hematol 2014;90(3):200-19
   PubMed Web of Science ®Google Scholar
• Wei Y, Kadia T, Tong W, et al. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 2010;6(7):976-8
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang Y, Zhou L, et al. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 2014;124(17):2687-97
   PubMed Web of Science ®Google Scholar
• Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5(10):761-72
   PubMed Web of Science ®Google Scholar
• Rahmani M, Yu C, Dai Y, et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003;63(23):8420-7
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Almenara J, et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 2003;63(9):2118-26
   PubMed Web of Science ®Google Scholar
• LaBonte MJ, Wilson PM, Fazzone W, et al. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res 2011;71(10):3635-48
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Yerram N, Dai Y, et al. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 2007;13(14):4280-90
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Venditti CA, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 2008;112(3):793-804
   PubMed Web of Science ®Google Scholar
• Kretzner L, Scuto A, Dino PM, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 2011;71(11):3912-20
   PubMed Web of Science ®Google Scholar
• Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007;6(1):21-2
   PubMed Web of Science ®Google Scholar
• Ueda H, Manda T, Matsumoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994;47(3):315-23
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kim YB, Terano H, et al.901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241(1):126-33
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62(17):4916-21
   PubMed Web of Science ®Google Scholar
• Newbold A, Lindemann RK, Cluse LA, et al. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008;7(5):1066-79
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Bishton M, Bates SE, et al. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax((R))). Epigenomics 2012;4(5):571-89
   PubMed Web of Science ®Google Scholar
• Sasakawa Y, Naoe Y, Noto T, et al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 2003;66(6):897-906
   PubMed Web of Science ®Google Scholar
• Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002;64(7):1079-90
   PubMed Web of Science ®Google Scholar
• Roychowdhury S, Baiocchi RA, Vourganti S, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst 2004;96(19):1447-57
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Scotto L, Marchi E, et al. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010;16(2):554-65
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Kramer LB, et al. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008;14(2):549-58
   PubMed Web of Science ®Google Scholar
• Holkova B, Kmieciak M, Bose P, et al. Phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma: updated results. Blood 2014;124:21
   Web of Science ®Google Scholar
• Khan SB, Maududi T, Barton K, et al. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004;125(2):156-61
   PubMed Web of Science ®Google Scholar
• Carniti C, Gimondi S, Vendramin A, et al. The combination of romidepsin and bendamustine is synergistically cytotoxic and reverses the malignant phenotype in preclinical models of T-cell lymphoma cancer research. (AACR Annual Meeting 2014). 2014
   Google Scholar
• Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Cosenza M, Civallero M, Fiorcari S, et al. Romidepsin synergizes with lenalidomide in T cell lymphoma cell lines by increasing reactive oxygen species and modulating PI3K/AKT and MAPK/ERK signaling pathways. Blood 2014;124:21
   Web of Science ®Google Scholar
• Zullo K, Guo Y, Cooke L, et al. The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin. Blood 2014;124:21
   Web of Science ®Google Scholar
• Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148(2):256-67
   PubMed Web of Science ®Google Scholar
• Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011;20(8):1151-8
   PubMed Web of Science ®Google Scholar
• Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2(6):325-32
   PubMedGoogle Scholar
• Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8(3):718-28
   PubMed Web of Science ®Google Scholar
• Noonan AM, Eisch RA, Liewehr DJ, et al. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Clin Cancer Res 2013;19(11):3095-104
   PubMed Web of Science ®Google Scholar
• Amiri-Kordestani L, Luchenko V, Peer CJ, et al. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res 2013;19(16):4499-507
   PubMed Web of Science ®Google Scholar
• Odenike OM, Alkan S, Sher D, et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008;14(21):7095-101
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011;117(2):336-42
   PubMed Web of Science ®Google Scholar
• Molife LR, Attard G, Fong PC, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Annals Oncol 2010;21(1):109-13
   PubMed Web of Science ®Google Scholar
• Otterson GA, Hodgson L, Pang H, Vokes EE; Cancer, Leukemia Group B. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 2010;5(10):1644-8
   PubMed Web of Science ®Google Scholar
• Stadler WM, Margolin K, Ferber S, et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006;5(1):57-60
   PubMed Web of Science ®Google Scholar
• Whitehead RP, Rankin C, Hoff PM, et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 2009;27(5):469-75
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98(9):2865-8
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117(22):5827-34
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28(29):4485-91
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30(6):631-6
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 2014;7(1):11
   PubMed Web of Science ®Google Scholar
• Fanale MA, Hagemeister FB, Fayad L, et al. A phase I trial of alisertib plus romidepsin for relapsed/refractory aggressive B- and T-cell lymphomas. Blood 2014;124:21
   Web of Science ®Google Scholar
• Lunning MA, Ruan J, Nair S, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results. JCO 2014;32: ASCO Annual Meeting
   Google Scholar
• Dai Chihara MP, Oki Y, Fayad L, et al. Phase I study of romidepsin in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma. Blood 2014;124:21
   Web of Science ®Google Scholar
• Jehan Dupuis M, Morschhauser F, Ghesquieres H, et al. Final Analysis of the RO-CHOP phase Ib/II study: romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL). Blood 2014;124:21
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128(4):683-92
   PubMed Web of Science ®Google Scholar
• Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262(2):75-83
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420-32
   PubMed Web of Science ®Google Scholar
• Anas younes BC. Lymphoma: diagnosis and treatment. Humana Press, London; 2013
   Google Scholar
• Arrighetti N, Corno C, Gatti L. Drug combinations with HDAC inhibitors in antitumor therapy. Crit Rev Oncog 2015;20(1-2):83-117
   PubMedGoogle Scholar
• Dasmahapatra G, Patel H, Friedberg J, et al. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Mol Cancer Ther 2014;13(12):2886-97
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63(13):3637-45
   PubMed Web of Science ®Google Scholar
• Miyanaga A, Gemma A, Noro R, et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008;7(7):1923-30
   PubMed Web of Science ®Google Scholar